{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:30:34Z","timestamp":1787679034109,"version":"build-2784847793"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003051 82072606"],"award-info":[{"award-number":["82003051 82072606"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Several issues on neoadjuvant imatinib therapy remain controversial despite its widespread application for rectal gastrointestinal stromal tumors (GIST). We aimed to describe the clinicopathological characteristics of this specific population, and compare the surgical and oncologic outcomes between patients with or without neoadjuvant imatinib therapy.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Patients and methods:<\/jats:bold>\n                    A cohort of 58 consecutive locally advanced rectal GIST patients receiving surgical treatment between January 2007 and July 2019 at Sun Yat-sen University Cancer Center and Yunnan Cancer Hospital was retrospectively analyzed. Recurrence-free survival (RFS) and overall survival (OS) were estimated using Kaplan-Meier method.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    There were 33 (56.9%) patients who received neoadjuvant imatinib therapy. Among them, 20 (60.6%) patients had partial response (PR) as their best response, 11 (33.3%) patients had stable disease (SD), and 2 (6.1%) patients had progressive disease (PD). The median tumor size reduced from 5.2 to 4.0\u00a0cm after treatment (\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001), and an attained \u201cmaximal response\u201d was primarily achieved (32\/33) on the 12th month after treatment. The most common adverse event was anemia. There were 27 adverse events occurred, most of which were grade 1 (19\/27). With respect to intraoperative and postoperative surgical outcomes, no significant difference was found between patients with or without neoadjuvant Imatinib therapy except that patients with neoadjuvant treatment had a significant higher rate of preventive ileostomy (\n                    <jats:italic>p<\/jats:italic>\n                    = 0.004). Patients received neoadjuvant treatment had a superior 2-years RFS outcome than those without, though the difference was no significant (91.7% vs. 78.9%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.203). There were no significant differences in the 2-years OS rates (95.2% vs. 91.3%,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.441).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Neoadjuvant imatinib therapy is an effective and safe treatment for locally advanced rectal GISTs. Further studies are warranted to validate the long-term prognostic benefit for patients with rectal GISTs receiving neoadjuvant imatinib therapy.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2022.950101","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T04:51:56Z","timestamp":1664254316000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Weihao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binyi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1245\/s10434-014-3632-7","article-title":"Analysis of prognostic factors impacting oncologic outcomes after neoadjuvant tyrosine kinase inhibitor therapy for gastrointestinal stromal tumors","volume":"21","author":"Bednarski","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1001\/jamasurg.2014.2881","article-title":"Conditional disease-free survival after surgical resection of gastrointestinal stromal tumors: A multi-institutional analysis of 502 patients","volume":"150","author":"Bischof","year":"2015","journal-title":"JAMA Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali","year":"2022","journal-title":"Ann. Oncol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1007\/s11605-020-04843-9","article-title":"Prognostic factors after neoadjuvant imatinib for newly diagnosed primary gastrointestinal stromal tumor","volume":"25","author":"Cavnar","year":"2021","journal-title":"J. Gastrointest. Surg."},{"key":"B5","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.1245\/s10434-017-6087-9","article-title":"Rectal gastrointestinal stromal tumor (GIST) in the era of imatinib: Organ preservation and improved oncologic outcome","volume":"24","author":"Cavnar","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1634\/theoncologist.13-S2-4","article-title":"Response evaluation of gastrointestinal stromal tumors","volume":"13","author":"Choi","year":"2008","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The clavien-dindo classification of surgical complications: Five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann. Surg."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/s0140-6736(09)60500-6","article-title":"Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial","volume":"373","author":"Dematteo","year":"2009","journal-title":"Lancet London, Engl."},{"key":"B9","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/hupa.2002.123545","article-title":"Diagnosis of gastrointestinal stromal tumors: A consensus approach","volume":"33","author":"Fletcher","year":"2002","journal-title":"Hum. Pathol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00384-013-1769-7","article-title":"Laparoscopic sphincter-preserving surgery (intersphincteric resection) after neoadjuvant imatinib treatment for gastrointestinal stromal tumor (GIST) of the rectum","volume":"29","author":"Fujimoto","year":"2014","journal-title":"Int. J. Colorectal Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1245\/s10434-016-5706-1","article-title":"Preoperative chemotherapy and survival for large anorectal gastrointestinal stromal tumors: A national analysis of 333 cases","volume":"24","author":"Hawkins","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Sci. (New York, NY)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/1471-2407-14-156","article-title":"Primary localized rectal\/pararectal gastrointestinal stromal tumors: Results of surgical and multimodal therapy from the French sarcoma group","volume":"14","author":"Huynh","year":"2014","journal-title":"BMC cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1245\/s10434-012-2647-1","article-title":"Gastrointestinal stromal tumor of the rectum: Results of surgical and multimodality therapy in the era of imatinib","volume":"20","author":"Jakob","year":"2013","journal-title":"Ann. Surg. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/s0140-6736(13)60106-3","article-title":"Gastrointestinal stromal tumour","volume":"382","author":"Joensuu","year":"2013","journal-title":"Lancet London, Engl."},{"key":"B16","doi-asserted-by":"publisher","first-page":"5155","DOI":"10.21873\/anticanres.11936","article-title":"Neoadjuvant imatinib therapy followed by intersphincteric resection for low rectal gastrointestinal stromal tumors","volume":"37","author":"Kaneko","year":"2017","journal-title":"Anticancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12957-016-0837-1","article-title":"Neoadjuvant imatinib treatment and laparoscopic anus-preserving surgery for a large gastrointestinal stromal tumor of the rectum","volume":"14","author":"Kyo","year":"2016","journal-title":"World J. Surg. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/jso.23562","article-title":"Treatment strategy of rectal gastrointestinal stromal tumor (GIST)","volume":"109","author":"Liu","year":"2014","journal-title":"J. Surg. Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.2147\/cmar.s307426","article-title":"The combination of neoadjuvant therapy and surgical resection: A safe and effective treatment for rectal gastrointestinal stromal tumors","volume":"13","author":"Liu","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/j.1463-1318.2010.02442.x","article-title":"The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour","volume":"13","author":"Machlenkin","year":"2011","journal-title":"Colorectal Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1097\/01.pas.0000172190.79552.8b","article-title":"Gastrointestinal stromal tumors of the stomach in children and young adults: A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature","volume":"29","author":"Miettinen","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ejso.2020.02.033","article-title":"Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort","volume":"46","author":"Ns","year":"2020","journal-title":"Eur. J. Surg. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3978\/j.issn.2078-6891.2015.088","article-title":"Multimodality therapy of rectal gastrointestinal stromal tumors in the era of imatinib-an Indian series","volume":"7","author":"Pai","year":"2016","journal-title":"J. Gastrointest. Oncol."},{"key":"B24","first-page":"8118","article-title":"KIT activation is a ubiquitous feature of gastrointestinal stromal tumors","volume":"61","author":"Rubin","year":"2001","journal-title":"Cancer Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/j.ejso.2011.06.005","article-title":"Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes","volume":"37","author":"Rutkowski","year":"2011","journal-title":"Eur. J. Surg. Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jso.23223","article-title":"Surgical management of rectal gastrointestinal stromal tumors","volume":"107","author":"Tielen","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s40615-019-00605-9","article-title":"Racial disparity in incidence and survival for gastrointestinal stromal tumors (GISTs): An analysis of SEER database","volume":"6","author":"Ulanja","year":"2019","journal-title":"J. Racial Ethn. Health Disparities"},{"key":"B28","doi-asserted-by":"publisher","first-page":"536","DOI":"10.6004\/jnccn.2018.0025","article-title":"Soft tissue sarcoma, version 2.2018, NCCN clinical practice guidelines in Oncology","volume":"16","author":"von Mehren","year":"2018","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/jso.26628","article-title":"The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional study","volume":"124","author":"Yang","year":"2021","journal-title":"J. Surg. Oncol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.950101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T04:52:03Z","timestamp":1664254323000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.950101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,27]]},"references-count":29,"alternative-id":["10.3389\/fphar.2022.950101"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.950101","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,27]]},"article-number":"950101"}}